GOSS Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Updat
GOSS Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Story updates
11:01:15 AM UTC
SquawkNews
GOSS Gossamer Bio announces FDA regulatory update and reacquisition of worldwide rights related to seralutinib and provides a business update Gossamer Bio - plans NDA submission for seralutinib in pah in September 2026 - Reacquires worldwide development and commercial rights to seralutinib from chiesi - Chiesi to make one-time $5M payment to Gossamer Gossamer Bio Inc: Co and chiesi agreed to terminate their collaboration and license agreement
11:08:17 AM UTC
SquawkNews
Gossamer Bio announced a...
GOSS Gossamer Bio announces FDA regulatory update and reacquisition of worldwide rights related to seralutinib and provides a business update Gossamer Bio - plans NDA submission for seralutinib in pah in September 2026 - Reacquires worldwide development and commercial rights to seralutinib from chiesi - Chiesi to make one-time $5M payment to Gossamer Gossamer Bio Inc: Co and chiesi agreed to terminate their collaboration and license agreement